RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ascendis Pharma A/S Stock

Ascendis Pharma A/S P/S 2024

Ascendis Pharma A/S P/S

15.59

Ticker

ASND

ISIN

US04351P1012

WKN

A14M6X

As of Jul 26, 2024, Ascendis Pharma A/S's P/S ratio stood at 15.59, a -9.62% change from the 17.25 P/S ratio recorded in the previous year.

The Ascendis Pharma A/S P/S history

Ascendis Pharma A/S Aktienanalyse

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Ascendis Pharma A/S's P/S Ratio

Ascendis Pharma A/S's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Ascendis Pharma A/S's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Ascendis Pharma A/S's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Ascendis Pharma A/S’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Ascendis Pharma A/S stock

What is the price-to-earnings ratio of Ascendis Pharma A/S?

The price-earnings ratio of Ascendis Pharma A/S is currently 15.59.

How has the price-earnings ratio of Ascendis Pharma A/S changed compared to last year?

The price-to-earnings ratio of Ascendis Pharma A/S has increased by -9.62% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Ascendis Pharma A/S high compared to other companies?

Yes, the price-to-earnings ratio of Ascendis Pharma A/S is high compared to other companies.

How does an increase in the price-earnings ratio of Ascendis Pharma A/S affect the company?

An increase in the price-earnings ratio of Ascendis Pharma A/S would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Ascendis Pharma A/S affect the company?

A decrease in the price-earnings ratio of Ascendis Pharma A/S would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Ascendis Pharma A/S?

Some factors that influence the price-earnings ratio of Ascendis Pharma A/S are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Ascendis Pharma A/S pay?

Over the past 12 months, Ascendis Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascendis Pharma A/S is expected to pay a dividend of 0 EUR.

What is the dividend yield of Ascendis Pharma A/S?

The current dividend yield of Ascendis Pharma A/S is .

When does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascendis Pharma A/S?

Ascendis Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Ascendis Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascendis Pharma A/S located?

Ascendis Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascendis Pharma A/S from 7/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/26/2024.

When did Ascendis Pharma A/S pay the last dividend?

The last dividend was paid out on 7/26/2024.

What was the dividend of Ascendis Pharma A/S in the year 2023?

In the year 2023, Ascendis Pharma A/S distributed 0 EUR as dividends.

In which currency does Ascendis Pharma A/S pay out the dividend?

The dividends of Ascendis Pharma A/S are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ascendis Pharma A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.